Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 9/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29888274 | 1.00 | TDP1 (0.50) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL29788829 | 0.87 | TDP1 (0.56) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL1424697 | 0.87 | TDP1 (0.56) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL1636077 | 0.86 | TDP1 (0.60) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL29902915 | 0.85 | TDP1 (0.54) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL2481319 | 0.85 | TDP1 (0.54) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL3634865 | 0.83 | TSHR (0.55) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL29361654 | 0.82 | TDP1 (0.54) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL57498 | 0.82 | TDP1 (0.54) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL31462805 | 0.82 | TDP1 (0.52) | TDP1ATMALDH1A1HIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12275717-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| WO-2024215809-A2 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2024-10-03 | — | — | US | disclosed |
| WO-2024175450-A1 | SUBSTITUTED S-ALANINATE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-29 | — | — | WO | disclosed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| EP-0287951-B1 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMA CO LTD (JP) | 1996-07-03 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| US-5495020-A | CHEMICAL INTERMEDIATE FOR BACTERICIDES, MICROBIOCIDES, DISINFECTANTS; SIDE EFFECT REDUCTION, ABSORPTION | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1996-02-27 | — | — | US | disclosed |
| EP-0565132-A2 | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
| EP-0531958-A1 | 6-Aminoquinolones, their synthesis and their use as antibacterial agents | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-03-17 | — | — | EP | disclosed |
| EP-0287951-A2 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
| EP-0028698-B1 | QUINOLINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS | Tanabe Seiyaku Co., Ltd. (JP) | 1982-12-22 | — | — | EP | disclosed |
| US-4327101-A | Quinoline compound useful as antibacterial agents in warm-blooded animals | TANABE SEIKAKU CO., LTD. (JP) | 1982-04-27 | — | — | US | disclosed |
| EP-0028698-A1 | Quinoline compounds, process for their preparation, and pharmaceutical compositions | Tanabe Seiyaku Co., Ltd. (JP) | 1981-05-20 | — | — | EP | disclosed |
| US-3998642-A | Silver halide emulsions with incorporated 4,6-difluorophenolic couplers | EASTMAN KODAK COMPANY (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275717-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | TDP1 3813/4885ATM 562/4885ALDH1A1 3735/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | TDP1 940/4885ATM 2630/4885ALDH1A1 1178/4885 |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | TDP1 510/4885ATM 2023/4885ALDH1A1 1786/4885 |
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | TDP1 2988/4885ATM 1614/4885ALDH1A1 4593/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | TDP1 3283/4885ATM 575/4885ALDH1A1 2320/4885 |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | TDP1 1798/4885ATM 42/4885ALDH1A1 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.